130 related articles for article (PubMed ID: 34814185)
21. Infantile inflammatory myofibroblastic tumors: clinicopathological and molecular characterization of 12 cases.
Lopez-Nunez O; John I; Panasiti RN; Ranganathan S; Santoro L; Grélaud D; Wu T; Buccoliero AM; Casanova M; Alaggio R; Surrey LF
Mod Pathol; 2020 Apr; 33(4):576-590. PubMed ID: 31690781
[TBL] [Abstract][Full Text] [Related]
22. Clinical significance of ROS1 5' deletions in non-small cell lung cancer.
Capizzi E; Dall'Olio FG; Gruppioni E; Sperandi F; Altimari A; Giunchi F; Fiorentino M; Ardizzoni A
Lung Cancer; 2019 Sep; 135():88-91. PubMed ID: 31447007
[TBL] [Abstract][Full Text] [Related]
23. A Novel CASC15-ALK and TFG-ROS1 Fusion Observed in Uterine Inflammatory Myofibroblastic Tumor.
Chang B; Wang Z; Ren M; Yao Q; Zhao L; Zhou X
Int J Gynecol Pathol; 2023 Sep; 42(5):451-459. PubMed ID: 36730016
[TBL] [Abstract][Full Text] [Related]
24. Chromoplectic TPM3-ALK rearrangement in a patient with inflammatory myofibroblastic tumor who responded to ceritinib after progression on crizotinib.
Mansfield AS; Murphy SJ; Harris FR; Robinson SI; Marks RS; Johnson SH; Smadbeck JB; Halling GC; Yi ES; Wigle D; Vasmatzis G; Jen J
Ann Oncol; 2016 Nov; 27(11):2111-2117. PubMed ID: 27742657
[TBL] [Abstract][Full Text] [Related]
25. ROS1-ADGRG6: a case report of a novel ROS1 oncogenic fusion variant in lung adenocarcinoma and the response to crizotinib.
Xu S; Wang W; Xu C; Li X; Ye J; Zhu Y; Ge T
BMC Cancer; 2019 Aug; 19(1):769. PubMed ID: 31382924
[TBL] [Abstract][Full Text] [Related]
26. A case of an inflammatory myofibroblastic tumor in the lung which expressed TPM3-ALK gene fusion.
Kinoshita Y; Tajiri T; Ieiri S; Nagata K; Taguchi T; Suita S; Yamazaki K; Yoshino I; Maehara Y; Kohashi K; Yamamoto H; Oda Y; Tsuneyoshi M
Pediatr Surg Int; 2007 Jun; 23(6):595-9. PubMed ID: 17063337
[TBL] [Abstract][Full Text] [Related]
27. A single-tube multiplexed assay for detecting ALK, ROS1, and RET fusions in lung cancer.
Lira ME; Choi YL; Lim SM; Deng S; Huang D; Ozeck M; Han J; Jeong JY; Shim HS; Cho BC; Kim J; Ahn MJ; Mao M
J Mol Diagn; 2014 Mar; 16(2):229-43. PubMed ID: 24418728
[TBL] [Abstract][Full Text] [Related]
28. Safety and Efficacy of Crizotinib in Patients With Advanced or Metastatic ROS1-Rearranged Lung Cancer (EUCROSS): A European Phase II Clinical Trial.
Michels S; Massutí B; Schildhaus HU; Franklin J; Sebastian M; Felip E; Grohé C; Rodriguez-Abreu D; Abdulla DSY; Bischoff H; Brandts C; Carcereny E; Corral J; Dingemans AC; Pereira E; Fassunke J; Fischer RN; Gardizi M; Heukamp L; Insa A; Kron A; Menon R; Persigehl T; Reck M; Riedel R; Rothschild SI; Scheel AH; Scheffler M; Schmalz P; Smit EF; Limburg M; Provencio M; Karachaliou N; Merkelbach-Bruse S; Hellmich M; Nogova L; Büttner R; Rosell R; Wolf J
J Thorac Oncol; 2019 Jul; 14(7):1266-1276. PubMed ID: 30978502
[TBL] [Abstract][Full Text] [Related]
29. Clinical Activity of Crizotinib in Lung Adenocarcinoma Harboring a Rare ZCCHC8-ROS1 Fusion.
Hicks JK; Boyle T; Albacker LA; Madison R; Frampton G; Creelan BC
J Thorac Oncol; 2018 Aug; 13(8):e148-e150. PubMed ID: 30049378
[No Abstract] [Full Text] [Related]
30. Targeting ROS1 Rearrangements in Non-small Cell Lung Cancer: Crizotinib and Newer Generation Tyrosine Kinase Inhibitors.
Morris TA; Khoo C; Solomon BJ
Drugs; 2019 Aug; 79(12):1277-1286. PubMed ID: 31313100
[TBL] [Abstract][Full Text] [Related]
31. Molecular pathways: ROS1 fusion proteins in cancer.
Davies KD; Doebele RC
Clin Cancer Res; 2013 Aug; 19(15):4040-5. PubMed ID: 23719267
[TBL] [Abstract][Full Text] [Related]
32. Pulmonary inflammatory myofibroblastic tumor and IgG4-related inflammatory pseudotumor: a diagnostic dilemma.
Bhagat P; Bal A; Das A; Singh N; Singh H
Virchows Arch; 2013 Dec; 463(6):743-7. PubMed ID: 24100523
[TBL] [Abstract][Full Text] [Related]
33. [TFG-ROS1 fusion positive inflammatory myofibroblastoma of uterus: report of a case].
Zhu HT; Wang J; Shen XJ
Zhonghua Bing Li Xue Za Zhi; 2023 Jun; 52(6):618-620. PubMed ID: 37263929
[TBL] [Abstract][Full Text] [Related]
34. Novel SLC12A2-ROS1 Fusion in Non-Small Cell Lung Cancer with a Significant Response to Crizotinib: The Importance of Choosing the Appropriate Next-Generation Sequencing Assay.
Rodríguez-Antolín C; Rosas-Alonso R; Cruz P; Higuera O; Sánchez-Cabrero D; Esteban-Rodríguez I; Peláez-García A; Fernández Montaño VE; Rodríguez-Jiménez C; Ibáñez de Cáceres I; de Castro J
Oncologist; 2021 Jun; 26(6):e908-e912. PubMed ID: 33682977
[TBL] [Abstract][Full Text] [Related]
35. Targeting ALK With Crizotinib in Pediatric Anaplastic Large Cell Lymphoma and Inflammatory Myofibroblastic Tumor: A Children's Oncology Group Study.
Mossé YP; Voss SD; Lim MS; Rolland D; Minard CG; Fox E; Adamson P; Wilner K; Blaney SM; Weigel BJ
J Clin Oncol; 2017 Oct; 35(28):3215-3221. PubMed ID: 28787259
[TBL] [Abstract][Full Text] [Related]
36. ALK, ROS1 and RET fusions in 1139 lung adenocarcinomas: a comprehensive study of common and fusion pattern-specific clinicopathologic, histologic and cytologic features.
Pan Y; Zhang Y; Li Y; Hu H; Wang L; Li H; Wang R; Ye T; Luo X; Zhang Y; Li B; Cai D; Shen L; Sun Y; Chen H
Lung Cancer; 2014 May; 84(2):121-6. PubMed ID: 24629636
[TBL] [Abstract][Full Text] [Related]
37. On the relevance of a testing algorithm for the detection of ROS1-rearranged lung adenocarcinomas.
Mescam-Mancini L; Lantuéjoul S; Moro-Sibilot D; Rouquette I; Souquet PJ; Audigier-Valette C; Sabourin JC; Decroisette C; Sakhri L; Brambilla E; McLeer-Florin A
Lung Cancer; 2014 Feb; 83(2):168-73. PubMed ID: 24380695
[TBL] [Abstract][Full Text] [Related]
38. Crizotinib-Resistant ROS1 Mutations Reveal a Predictive Kinase Inhibitor Sensitivity Model for ROS1- and ALK-Rearranged Lung Cancers.
Facchinetti F; Loriot Y; Kuo MS; Mahjoubi L; Lacroix L; Planchard D; Besse B; Farace F; Auger N; Remon J; Scoazec JY; André F; Soria JC; Friboulet L
Clin Cancer Res; 2016 Dec; 22(24):5983-5991. PubMed ID: 27401242
[TBL] [Abstract][Full Text] [Related]
39. ROS1-positive Inflammatory Myofibroblastic Tumor of the Small Bowel Causing Obstruction: A Case Report.
Budylev A; Solar I; Kessner R; Aizic A
J Radiol Case Rep; 2022 Jan; 16(1):14-21. PubMed ID: 35586084
[TBL] [Abstract][Full Text] [Related]
40. Curable response to crizotinib in a patient with liver metastatic inflammatory myofibroblastic tumour carrying a TFG-ROS1 fusion.
Yan H; Du L; Zheng T; Liu J
Liver Int; 2022 Dec; 42(12):2900-2902. PubMed ID: 36226472
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
